Jpmorgan Chase & CO Prometheus Biosciences, Inc. Transaction History

Jpmorgan Chase & CO

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 18, 2023	BUY	$103.46 - $126.29 $4.5 Million - $5.49 Million	43,468 Added 74.79%	101,586 $10.9 Million
Q1 2023 May 11, 2023	SELL	$103.46 - $126.29 $7.13 Million - $8.71 Million	-68,957 Reduced 54.26%	58,118 $6.24 Million
Q4 2022 Feb 13, 2023	BUY	$36.06 - $117.21 $1.62 Million - $5.27 Million	44,966 Added 54.76%	127,075 $14 Million
Q3 2022 Nov 14, 2022	SELL	$28.17 - $59.01 $8,197 - $17,171	-291 Reduced 0.35%	82,109 $4.85 Million
Q2 2022 Aug 11, 2022	SELL	$22.39 - $38.94 $11,799 - $20,521	-527 Reduced 0.64%	82,400 $2.33 Million
Q1 2022 May 11, 2022	BUY	$30.13 - $50.0 $2.05 Million - $3.4 Million	67,975 Added 454.62%	82,927 $3.13 Million
Q4 2021 Feb 10, 2022	BUY	$22.28 - $39.54 $236,301 - $419,361	10,606 Added 244.04%	14,952 $591,000
Q3 2021 Nov 12, 2021	BUY	$20.89 - $26.96 $90,787 - $117,168	4,346 New	4,346 $103,000

29.6K

Ticker RXDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,904,100
Description
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.